v3.26.1
Description of Business and Basis of Preparation - Additional Information (Detail)
$ / shares in Units, $ in Thousands
6 Months Ended
May 28, 2026
shares
Jun. 30, 2026
USD ($)
$ / shares
shares
Jun. 26, 2026
$ / shares
shares
Jun. 25, 2026
shares
May 29, 2026
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Product Information [Line Items]            
Ownership rights, description   The Company owns 100% of the rights to SCY-247, as well as additional fungerp compounds in preclinical and discovery stages of development. The FDA has granted Qualified Infectious Disease Product status, Fast Track, and Orphan Drug designations for the oral formulation of SCY-247.        
Owns percentage of right   100.00%        
Accumulated deficit | $   $ (399,046)       $ (385,144)
Cash and cash equivalents and investments | $   $ 71,100        
Reverse stock split conversion ratio 0.125          
Common stock, shares authorized (in shares) 150,000,000 60,000,000 65,000,000 23,750,000 18,750,000 60,000,000
Common stock, shares issued (in shares) 79,459,299 9,949,609     9,932,359 5,442,688
Common stock, shares outstanding (in shares) 79,459,299 9,949,609     9,932,359 5,442,688
Common stock, par value (in dollars per share) | $ / shares   $ 0.001 $ 0.001     $ 0.001